Search Results - "Truman, Matt"

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial by Wu, Yi-Long, Prof, Lee, Jin Soo, MD, Thongprasert, Sumitra, MD, Yu, Chong-Jen, Prof, Zhang, Li, Prof, Ladrera, Guia, MD, Srimuninnimit, Vichien, MD, Sriuranpong, Virote, MD, Sandoval-Tan, Jennifer, MD, Zhu, Yunzhong, Prof, Liao, Meilin, Prof, Zhou, Caicun, MD, Pan, Hongming, MD, Lee, Victor, FRCR, Chen, Yuh-Min, PhD, Sun, Yan, MD, Margono, Benjamin, PhD, Fuerte, Fatima, MD, Chang, Gee-Chen, MD, Seetalarom, Kasan, MD, Wang, Jie, Prof, Cheng, Ashley, MBBS, Syahruddin, Elisna, PhD, Qian, Xiaoping, MD, Ho, James, MD, Kurnianda, Johan, SPPD, Liu, Hsingjin Eugene, MD, Jin, Kate, MD, Truman, Matt, MSc, Bara, Ilze, MD, Mok, Tony, Prof

“…Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly…”
Get full text

Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS by Dall'Era, Maria, Kalunian, Kenneth, Solomons, Neil, Truman, Matt, Hodge, Lucy S, Yap, Ernie, Askanase, Anca D

“…Introduction High-dose glucocorticoid (GC)-based dual immunosuppressive treatment regimens are still frequently used in active lupus nephritis (LN) despite…”
Get full text

P87 Comparison of a voclosporin-based, triple immunotherapy regimen to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV plus AURORA 1 studies and ALMS by Dall’Era, Maria, Kalunian, Kenneth, Askanase, Anca, Solomons, Neil, Truman, Matt, Hodge, Lucy, Yap, Ernie

“…ObjectiveEarly reduction in proteinuria after initial treatment has been associated with improved long-term kidney outcomes in lupus nephritis (LN). The…”
Get full text

A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease by Roger, Simon D., Suranyi, Michael G., Walker, Rowan G.

“…ABSTRACT Objective: To compare injection site pain of subcutaneous (sc) epoetin beta and darbepoetin alfa in adult patients with chronic kidney disease…”
Get full text

Efficacy and Safety of Voclosporin Over 3 Years in Patients With Severe Lupus Nephritis: FR-OR58 by Menn-Josephy, Hanni, Truman, Matt, Palmen, Mary, Leher, Henry

Get full text

Voclosporin Is Effective in Achieving Complete Renal Response in Severe Lupus Nephritis: SA-OR31 by Menn-Josephy, Hanni, Truman, Matt, Palmen, Mary, Mina-Osorio, Paola

Get full text

468 Voclosporin-based, triple-immunosuppressive therapy vs high-dose glucocorticoid-based dual-immunotherapy for lupus nephritis: a propensity analysis by Yap, Ernie, Askanase, Anca, Kalunian, Kenneth, Dall'era, Maria, Hodge, Lucy, Truman, Matt, Solomons, Neil

“…Abstract Background and Aims Voclosporin is a second generation calcineurin inhibitor (CNI) approved for the treatment of adults with active lupus nephritis…”
Get full text

Comparison of Dual-Immunosuppressive Therapy and a Voclosporin-Based, Triple-Immunosuppressive Regimen for Lupus Nephritis: A Propensity Analysis of ALMS and AURORA 1: SA-PO877 by Yap, Ernie, Dall'Era, Maria, Truman, Matt, Hodge, Lucy S., Solomons, Neil

Get full text

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy by Mok, Tony, Wu, Yi-Long, Lee, Jin Soo, Yu, Chong-Jen, Sriuranpong, Virote, Sandoval-Tan, Jennifer, Ladrera, Guia, Thongprasert, Sumitra, Srimuninnimit, Vichien, Liao, Meilin, Zhu, Yunzhong, Zhou, Caicun, Fuerte, Fatima, Margono, Benjamin, Wen, Wei, Tsai, Julie, Truman, Matt, Klughammer, Barbara, Shames, David S, Wu, Lin

“…Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched…”
Get full text

Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset by Youssef, Peter, Marcal, Bruno, Button, Peter, Truman, Matt, Bird, Paul, Griffiths, Hedley, Roberts, Lynden, Tymms, Kathleen, Littlejohn, Geoff

“…Objective. To provide real-world evidence about the reasons why Australian rheumatologists cease biologic (b) and targeted synthetic (ts) disease-modifying…”
Get full text

Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE) by Woodward, Natasha, De Boer, Richard H., Redfern, Andrew, White, Michelle, Young, Jennifer, Truman, Matt, Beith, Jane

“…The primary objective of this study was to assess the safety and tolerability of combination pertuzumab, subcutaneous trastuzumab (Herceptin), and…”
Get full text

Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials by Locatelli, Francesco, Choukroun, Gabriel, Truman, Matt, Wiggenhauser, Alfons, Fliser, Danilo

“…Introduction Erythropoiesis-stimulating agents and iron are commonly used in patients with chronic kidney disease with the aim of correcting anemia and…”
Get full text

Safety of Subcutaneous Administration of Rituximab during the First-Line Treatment of Patients with Non-Hodgkin Lymphoma: The MabRella Study by Panizo, Carlos, Bekadja, Mohamed Amine, Meddeb, Balkis, Rigoroso Mendoza, Maria, Truman, Matt, Smith, Rodney, Baratè, Claudia

“…Background: Rituximab, administered intravenously (IV), is the mainstay of treatment for CD20+ B-cell non-Hodgkin lymphoma (NHL). A subcutaneous (SC)…”
Get full text

A multi‐centre, single‐arm, open‐label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R‐ITP1000 study) by Tran, Huyen, Brighton, Tim, Grigg, Andrew, McRae, Simon, Dixon, Joanna, Thurley, Daniel, Gandhi, Maher K., Truman, Matt, Marlton, Paula, Catalano, John

“…Summary The efficacy of a fixed‐dose rituximab schedule was prospectively explored in primary/acute refractory, relapsed or chronic (platelet count >10 × 109/l…”
Get full text

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome by Dall'Era, Maria, Levesque, Victoria, Solomons, Neil, Truman, Matt, Wofsy, David

“…Objective To identify factors associated with clinical outcome in patients with lupus nephritis. Methods Data from the Aspreva Lupus Management Study (ALMS)…”
Get full text

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial by Gridelli, Cesare, de Castro Carpeno, Javier, Dingemans, Anne-Marie C, Griesinger, Frank, Grossi, Francesco, Langer, Corey, Ohe, Yuichiro, Syrigos, Konstantinos, Thatcher, Nick, Das-Gupta, Ashis, Truman, Matt, Donica, Margarita, Smoljanovic, Vlatka, Bennouna, Jaafar

“…Bevacizumab treatment beyond progression has been investigated in breast and metastatic colorectal cancers. Avastin in All Lines Lung (AvaALL) is the first…”
Get more information

Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL by Nicholls, Dave, Barrett, Rina, Button, Peter, Truman, Matt, Bird, Paul, Roberts, Lynden, Tymms, Kathleen, Littlejohn, Geoffrey, Griffiths, Hedley

“…Background The comparative effectiveness of biologic treatment regimens in a real world Australian population is unknown. Aim To assess the effectiveness of…”
Get full text

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer by Mok, Tony, Ladrera, Guia, Srimuninnimit, Vichien, Sriuranpong, Virote, Yu, Chong-Jen, Thongprasert, Sumitra, Sandoval-Tan, Jennifer, Lee, Jin Soo, Fuerte, Fatima, Shames, David S, Klughammer, Barbara, Truman, Matt, Perez-Moreno, Pablo, Wu, Yi-long

“…Highlights • EGFR mutation is the main predictive biomarker for better outcomes with erlotinib. • Expression of HER2 and HER3 were not independently predictive…”
Get full text

Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial by McDonald, Stephen, Yiu, Sean, Su, Li, Gordon, Caroline, Truman, Matt, Lisk, Laura, Solomons, Neil, Bruce, Ian N, Bruce, Ian N, Payne, Katherine, Lunt, Mark, Peek, Niels, Geifman, Nophar, Gavan, Sean, Armitt, Gillian, Doherty, Patrick, Prattley, Jennifer, Azadbakht, Narges, Papazian, Angela, Sueur, Helen Le, Farrelly, Carmen, Richardson, Clare, Shabbir, Zunnaira, Hewitt, Lauren, McHugh, Neil, Gordon, Caroline, Reynolds, John, Young, Stephen, Jayne, David, Farewell, Vern, Su, Li, Pickering, Matthew, Lightstone, Elizabeth, Gilmore, Alyssa, Botto, Marina, Vyse, Timothy, Morris, David Lester, D’Cruz, D, Vital, Edward, Wittmann, Miriam, Emery, Paul, Beresford, Michael, Hedrich, Christian, Midgley, Angela, Gritzfeld, Jenna, Ehrenstein, Michael, Isenberg, David, Parvaz, Mariea, Dunnage, Jane, Batchelor, Jane, Holland, E, Upsall, Pauline

“…ObjectivesTo identify predictors of overall lupus and lupus nephritis (LN) responses in patients with LN.MethodsData from the Aspreva Lupus Management Study…”
Get full text

Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: A randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C) by Mok, Tony, Wu, Yi Long, Lee, Jin Soo, Yu, Chong-Jen, Sriuranpong, Virote, Wen, Wei, Tsai, Julie, Truman, Matt, Klughammer, Barbara, Wu, Lin

“…Abstract only 8021 Background: Biomarker analysis of tumor from FASTACT 2 confirmed predictive power of EGFR mut on the benefit of intercalated combination of…”
Get full text